Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19

Spyros Chalkias, Jordan Whatley, Frank Eder, Brandon Essink, Shishir Khetan, Paul Bradley, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Xiaoping Zhao, Andrea Sutherland, Xiaoying Shen, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Stephen Walsh, David C. Montefiori, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das
doi: https://doi.org/10.1101/2022.12.11.22283166

Article Information

doi 
https://doi.org/10.1101/2022.12.11.22283166
History 
  • December 13, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Spyros Chalkias, M.D.1,*,
  2. Jordan Whatley, M.D.2,
  3. Frank Eder, M.D.3,
  4. Brandon Essink, M.D.4,
  5. Shishir Khetan, M.D.5,
  6. Paul Bradley, M.D.6,
  7. Adam Brosz, M.D.7,
  8. Nichole McGhee, B.S.1,
  9. Joanne E. Tomassini, Ph.D.1,
  10. Xing Chen, Sc.D.1,
  11. Xiaoping Zhao, M.S.1,
  12. Andrea Sutherland, M.D., M.PH.1,
  13. Xiaoying Shen, Ph.D8,
  14. Bethany Girard, Ph.D.1,
  15. Darin K. Edwards, Ph.D.1,
  16. Jing Feng, M.S.1,
  17. Honghong Zhou, Ph.D.1,
  18. Stephen Walsh, M.D.9,
  19. David C. Montefiori, Ph.D.8,
  20. Lindsey R. Baden, M.D.9,
  21. Jacqueline M. Miller, M.D.1 and
  22. Rituparna Das, M.D., Ph.D.1
  1. 1Moderna, Inc., Cambridge, Massachusetts, USA
  2. 2Meridian Clinical Research, Baton Rouge, Louisiana, USA
  3. 3Meridian Clinical Research, LLC, Binghamton, New York
  4. 4Meridian Clinical Research, Omaha, Nebraska, USA
  5. 5Meridian Clinical Research, Rockville, Maryland, USA
  6. 6Meridian Clinical Research, Savannah, Georgia, USA
  7. 7Meridian Clinical Research, Grand Island, Nebraska, USA
  8. 8Department of Surgery and Duke Human Vaccine Institute, Durham, North Carolina, USA
  9. 9Brigham and Women’s Hospital, Boston, Massachusetts, USA
  1. ↵*Corresponding Author:
    Spyros Chalkias, M.D., Moderna, Inc., Cambridge, MA, USA 02141-2025, Email: spyros.chalkias{at}modernatx.com, Cell phone: 617-335-0744
Back to top
Posted December 13, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19
Spyros Chalkias, Jordan Whatley, Frank Eder, Brandon Essink, Shishir Khetan, Paul Bradley, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Xiaoping Zhao, Andrea Sutherland, Xiaoying Shen, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Stephen Walsh, David C. Montefiori, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das
medRxiv 2022.12.11.22283166; doi: https://doi.org/10.1101/2022.12.11.22283166
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area